• PKM2 inhibitor (compound 3k): Assay Workflows

  2026-09-08

  Build reproducible glycolysis and viability assays around PKM2 inhibitor (compound 3k), from DMSO stock preparation through orthogonal metabolic validation. Its cancer-cell activity and emerging macrophage-metabolism application support distinct workflows for tumor profiling, ovarian cancer therapy research, and mechanism testing.

• WRN–MSI Synthetic Lethality in Colorectal Cancer

  2026-09-08

  This PNAS study explains why mismatch repair-deficient, microsatellite-instable colorectal cancer cells depend on Werner helicase: WRN loss activates a p53–PUMA apoptotic program. Genetic depletion and ML216 treatment suppressed MSI colorectal cancer growth in cell and xenograft models, while p53 or PUMA disruption reduced the effect, providing a mechanistic framework for biomarker-guided WRN-targeted research.

• Thioguanine Workflow for EV71 and Cancer Assays

  2026-09-07

  Build a practical Thioguanine workflow around antiviral, oncology, and epigenetic readouts rather than relying on a single viability endpoint. The approach translates EV71 replication data into controlled dose–response, mechanism-aware assays while addressing solubility, cytotoxicity, and cross-model comparability.

• Firefly Luciferase mRNA: Assay Workflow Guide

  2026-09-07

  Learn how to use Firefly Luciferase mRNA as a sensitive control for delivery, translation, cell viability, and biodistribution studies. This practical guide connects ARCA capping and modified nucleotides with reproducible transfection workflows and emerging mRNA-LNP delivery research.

• Stable Isotope UHPLC–MS/MS for Methylated Purines

  2026-09-05

  The 2024 Analytical Chemistry study developed a stable isotope-diluted UHPLC–ESI-MS/MS workflow for accurate measurement of 12 purine ribonucleosides, including 10 methylated species. Enhanced ionization, chromatographic resolution of methylated isomers, and matrix-reduction steps enabled sensitive intracellular quantification relevant to RNA modification research, cancer metabolism studies, and biomarker discovery.

• (±)-Blebbistatin for Spatial Cell Mechanics

  2026-09-04

  Use (±)-Blebbistatin to reversibly reduce non-muscle myosin II activity while measuring migration, adhesion, and morphology with spatially resolved imaging. Inspired by panoramic cardiac mapping, this workflow links a mechanical perturbation to local cell behavior instead of treating an image as a purely descriptive endpoint.

• YTHDF1–THBS1 Control of Osteogenesis under Hypoxia

  2026-09-04

  The reference study identifies YTHDF1 as a hypoxia-responsive m6A reader that counteracts impaired osteogenic differentiation in MC3T3-E1 cells through post-transcriptional regulation of THBS1. Its combination of gene perturbation, osteogenic phenotyping, and RNA-level analyses provides a mechanistic framework for studying hypoxia-related bone loss in peri-implantitis.

• TEAC: From K+ Pores to Translational Strategy

  2026-09-03

  Tetraethylammonium chloride (TEAC) is more than a broad potassium-channel blocker: it is a mechanistic perturbation tool for connecting pore conduction with cellular, vascular, and translational phenotypes. This article integrates ion-channel biology, evidence from pancreatic beta-cell research, experimental design, product considerations, and strategic guidance for interpreting TEAC-driven results.

• AR Heterogeneity Shapes Castration and Enzalutamide Response

  2026-09-03

  Li and colleagues show that androgen receptor heterogeneity is not merely a descriptive feature of advanced prostate cancer: nuclear, mixed nuclear/cytoplasmic, and AR-low or negative states display different tumor behavior and responses to castration or enzalutamide. By combining patient samples, xenografts, isogenic genome-edited models, RNA sequencing, and combination treatment experiments, the study identifies BCL-2 as a potential vulnerability for AR-low or negative disease.

• HotStart Universal 2X Green qPCR Master Mix

  2026-09-02

  Build reproducible real-time PCR gene expression analysis around a hot-start enzyme, Green I fluorescence, and a universal ROX reference system. This workflow translates a finishing-pig Eucommia ulmoides leaf extract study into practical assay design, from tissue cDNA and dose-response panels to melt-curve verification and troubleshooting.

• Protein A/G Magnetic Beads: Practical IP Guide

  2026-09-02

  Protein A/G Magnetic Beads provide Fc-directed capture for antibody purification, immunoprecipitation, co-immunoprecipitation, and chromatin workflows from complex samples. This guide explains setup, controls, and troubleshooting while defining limits for Fc-lacking antibody fragments, unvalidated assay conditions, and diagnostic or medical use.

• FGFR3 Inhibition in SLC26A2 Chondrodysplasia

  2026-09-01

  The reference study combines genetic models, inducible postnatal deletion, chondrocyte assays, and pharmacological inhibition to show that excessive FGFR3 signaling contributes to SLC26A2-related skeletal dysplasia in mice. Its findings support FGFR3 pathway inhibition as a research direction for improving chondrocyte differentiation, survival, and bone microarchitecture, while leaving human efficacy and dosing questions unresolved.

• Rotenone and Mitochondria-to-Peroxisome Stress

  2026-09-01

  Rotenone is best known as a mitochondrial Complex I inhibitor, but its value extends to studying how mitochondrial stress may intersect with organelle quality control. This article translates new findings on MARCH5-dependent pre-peroxisome formation into a practical framework for designing mechanistically separated rotenone assays.

• BODIPY 581/591 C11 for Lipid Peroxidation

  2026-08-31

  BODIPY 581/591 C11 converts membrane oxidation into a measurable red-to-green fluorescence ratio, supporting live-cell lipid peroxidation detection without relying on a single intensity value. This workflow guide shows how to apply the probe to antioxidant capacity evaluation, nanozyme studies, and cardiovascular oxidative stress experiments while avoiding common interpretation errors.

• HyperFusion high-fidelity DNA polymerase for C. elegans PCR

  2026-08-31

  HyperFusion™ high-fidelity DNA polymerase combines proofreading accuracy with robust amplification of GC-rich, long, or inhibitor-containing templates. This article shows how to apply it to C. elegans genotyping, cloning, targeted sequencing, and mechanistic studies inspired by pheromone-linked neurodegeneration research.

7928 records 1/529 page Next 12345 下5页 Last page